Australian cancer and cardiovascular treatment provider GenesisCare, which is owned by KKR, has bought cancer center manager Cancer Partners UK from its private equity backer, Apposite Capital.
China VC firm Qiming Venture Partners has promoted healthcare specialist William Hu to managing partner with immediate effect.
Australian life sciences specialists Brandon Capital Partners and GBS Ventures will exit local drug developer Spinifex Pharmaceuticals after Novartis agreed to buy the business for $200 million in cash plus unspecified earn-outs.
Roger Hu, a director at Matrix Partners China, has teamed up with Yi Zheng, formerly vice president at Chinese dating app Momo, to launch a renminbi-denominated early-stage fund.
Crescent Capital Partners has agreed to acquire the Australian pathology operations of Healthscope for A$105 million ($80.8 million).
Singapore's Temasek Holdings is a member of a CVC Capital Partners-led consortium that has agreed to buy a controlling stake in US-based generic drug manufacturer Alvogen. The deal is said to value the company at $2 billion.
Wenzhou Kangning Hospital, the largest private psychiatric specialty care service provider in China backed by PE investors, has filed for an IPO in Hong Kong.
Indian dental clinic chain MyDentist has raised a INR500 million ($8 million) funding round led by Swiss impact investor LGT Venture Philanthropy, with participation by existing backers Seedfund and Asian Healthcare Fund (AHF).
For the past decade, Japan’s universities have been working with venture capital to commercialize their research. Recent developments in the public and private sectors suggest this relationship is evolving
La Renon, an Indian developer and manufacturer of pharmaceutical drugs and services, has raised INR1 billion ($16 million) in Series A funding from Sequoia Capital.
Neil Shen, managing partner at Sequoia Capital China, is supporting take-private bids for budget hotel operator Home Inns and online real estate agency E-House as a growing number of US-listed Chinese companies turn their attention to domestic listings.
Warburg Pincus has raised $241.5 million by reducing its stake in US-listed biopharmaceutical developer China Biologic Products.
Panasonic Healthcare, the Japanese medical equipment manufacturer in which KKR acquired a majority stake last year, has agreed to buy Bayer’s diabetes care business for EUR1.02 billion ($1.15 billion).
Hong Kong-based pharmaceutical developer Luqa Pharma has raised a $15 million Series A round of funding led by Morningside Ventures.
Quadria Capital, the Singapore and India-based private equity firm, has reached a final close on its maiden healthcare fund at $304 million.
CITIC Private Equity has made a partial exit from Chinese biotech player 3SBio as the company raised HK$5.51 billion ($711 million), two years after leaving NASDAQ in a take-private deal.
Fidelity Growth Partners India (FGPI) and affiliated US fund Fidelity Biosciences have invested $10 million in Medwell Ventures, operator of Nightingales specialty home healthcare services.
A consortium of Chinese investors including Shanghai Fosun Pharmaceutical Group, Hopu Investments, CEL Healthcare Fund and WuXi PharmaTech will acquire Ambrx, a US-based biotech pharmaceutical developer.
Hony Capital CEO John Zhao expects to see more control opportunities arising from domestic succession planning, cross-border expansion and restructuring. He explains how his firm is preparing the ground
Private equity investors see huge opportunities in China’s hospital space on the back of healthcare reforms. But valuations are high, doctors are in limited supply, and regulation can be a headache
BeiGene, a Chinese company that develops drugs to combat cancer, has raised RMB600 million ($97 million) in a funding round led by existing investors Hillhouse Capital and an undisclosed US-based life sciences-focused public investment fund.
Taiwan-based biopharmaceutical company JHL Biotech has raised a $45 million Series C round, led by an unnamed investor. Existing backer Milestone Capital also participated, along with newcomers Sungent BioVenture and Liwick Investment Management.
CLSA Capital Partners (CLSA CP) has invested RMB150 million ($24.5 million) in Coco Healthcare Products, a Chinese manufacturer of diapers for adults and babies. It plans to help the company boost its export business.